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Abstract
We previously reported an epidemiologically linked HIV-1 infected patient cohort in which a long-
term non-progressor (LTNP) infected two recipients who then exhibited normal disease
progression. Expression of patient-derived vpr sequences from each of the three cohort members
in mammalian cells tagged with GFP revealed a significant reduction in Vpr nuclear import and
virion incorporation uniquely from the LTNP, whereas Vpr from the two progressing recipients
displayed normal localisation and virion incorporation, implying a link between efficient Vpr nuclear
import and HIV disease progression. Importantly, an F72L point mutation in the LTNP was
identified for the first time as being uniquely responsible for decreased Vpr nuclear import.
Findings
The highly conserved HIV accessory protein Viral Protein
R (Vpr) is vital for HIV infection and replication in vivo,
particularly within non-dividing cells, including termi-
nally differentiated T-cells and macrophages where
nuclear envelope integrity is permanently maintained [1-
5]. On its own and within the context of HIV infection
[6,7], Vpr has been shown to localize to the nucleus and
induce G2 cell-cycle arrest through hyperphosphorylation
of p34-cdc2, which provides the most optimal environ-
ment for viral replication [8-13], followed closely by
apoptosis [14-21]. During HIV infection, Vpr associates
with the viral cDNA containing Pre-integration Complex
(PIC) increasing its affinity for components of the cellular
nuclear import machinery [22-25] through the activity of
2 distinct nuclear localization signals (NLSs) within its N-
[26] and C-termini [27], thus driving productive HIV
infection.
We previously reported [28] on a cohort spanning 1992 to
2000, comprising an HIV+  long-term non-progressor
(LTNP) (donor A) and two recipients (B and C) who upon
transmission (autumn and summer 1989 respectively)
from donor A progressed to AIDS. Vpr sequences derived
from HIV pro-viral DNA isolated from PBMCs as well as
circulating virus, revealed that sequences from the pro-
gressing recipients differed markedly to those of the LTNP
founder virus host, providing the first evidence for Vpr
positive selection during disease progression in an epide-
miologically-linked cohort (see also [29]).
In this study, cohort-derived GFP-Vpr mammalian cell
expression vectors were used to investigate Vpr subcellular
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localisation and nuclear import. In total, 4 HIV-1 vpr
clones were isolated from donor A (A1, A3, A5 and A6 cor-
responding to years 1996, 1998, 1999 and 2000), 4 from
recipient B (B3, B4, B5 and B6 corresponding to years
1997, 1998, 1998 and 1999) and 7 from recipient C (C2,
C3, C5, C6, C8, C10 and C11 from 1992, 1992, 1993,
1994, 1994, 1998 and 1999 respectively) and used to gen-
erate the GFP-Vpr expression constructs. Lipofectamine™
2000 (Invitrogen) was used to transfect constructs into
HeLa and COS-7 (not shown) cells, followed by imaging
14 hours post transfection using an Olympus FV-1000
confocal laser scanning microscope (CLSM), with similar
results. Initial analysis of late-stage vpr gene products from
all 3 donors revealed a reduction in nuclear fluorescence
accompanied by perinuclear accumulation for LTNP sam-
ple A6-2 (patient A, time-point 6, clone #2) (Fig. 1A(iii))
compared to pUC18-NL4.3 derived [30] wild-type GFP-
Vpr1–96 (Fig. 1A(ii)): a phenotype not observed in samples
from patients B (B6-4) nor C (C11-1) (Fig 1A(iv, v)).
Quantification of nuclear import was determined using
ImageJ analysis software [31] where the ratio of nuclear
(Fn) to cytoplasmic (Fc) fluorescence, subtracting back-
ground (B) was calculated, Fn/c = (Fn-B)/(Fc-B). A highly
significant (p < 0.0001) reduction in Fn/c was observed
between GFP-Vpr1–96 (Fn/c ~2.4) and GFP-VprA6-2 (Fn/c
~0.9) indicating a reduction in nuclear accumulation. No
significant difference in Fn/c was observed between GFP-
Vpr1–96 and GFP-VprB6-4 or GFP-VprC11-1 (Fig. 1B).
To establish if decreased Vpr nuclear accumulation was a
specifically conserved viral feature of the LTNP or an
acquired trait, GFP-Vpr constructs from early-cohort time-
points were analysed. Samples from 1996 (GFP-VprA1-2)
and 1998 (GFP-VprA3-1) (Fig. 1A(vi, vii)) both displayed
levels of nuclear accumulation comparable to wildtype
GFP-Vpr1–96  (Fig. 1B), implying that loss of nuclear
import occurred post 1998.
With the loss of efficient nuclear accumulation identified
as a late-stage LTNP trait, further analysis of late-stage
clones A6-3 and A6-5 (clone A6-5 data not shown as
sequence is homologous to A6-3) was performed, revealing
Fn/c values significantly lower than wildtype GFP-Vpr1–96
(Fig. 1B). Of interest, a single late-stage clone (GFP-VprA6-
4) displayed a small degree of nuclear accumulation (Fig.
1A(ix)), although at levels significantly reduced compared
to wildtype (Fig. 1B). Sequence analysis revealed that all
clones with reduced nuclear accumulation (VprA6-2 and
VprA6-3/5) contained a phenylalanine to leucine mutation
at amino acid position 72 (F72L) (Fig. 1C). This mutation
is absent in the nuclear localizing VprA6-4, which is other-
wise identical in sequence to late-stage samples VprA6-3/5.
Analysis of our database containing over 1200 published
and unpublished Vpr sequences revealed that the F72L
mutation has only been reported once previously [32].
To determine the specific role of F72L in abrogation of
Vpr nuclear import, an F72L substitution was engineered
into wildtype Vpr and an expression construct (GFP-
VprF72L) produced. Subsequent transfection (Fig. 1A(x))
revealed a reduction in GFP-VprF72L nuclear accumulation
when compared with wildtype GFP-Vpr1–96 (Fig. 1A(ii)),
in a similar fashion to clinically derived GFP-VprA6-2 (Fig.
1B), thus confirming F72L as a probable mechanism for
the observed reduction in nuclear accumulation within
late-stage LTNP samples. This reduction in nuclear import
was accompanied by an accumulation of GFP-Vpr protein
within the perinuclear region of the cell, concordant with
an area encompassing the proposed location of the Golgi.
Colocalisation studies with the Golgi-specific marker pro-
tein γ-adaptin revealed that Vpr proteins harbouring the
F72L point mutation, but not those with wildtype pheny-
lalanine, were localized to the Golgi apparatus, implying
that reduced nuclear accumulation could in part be attrib-
uted to this mislocalisation of GFP-Vpr (see Additional
file 1). The lack of colocalisation between F72L-contain-
ing Vpr proteins and the endoplasmic reticulum (ER)
marker Calnexin (Sigma, C-4731), confirmed that Vpr
mislocalisation to the Golgi is not a result of general mis-
targeting (see Additional file 2).
Although the precise pathways involved are still debated,
efficient nuclear export [33] and/or cytoplasmic retention
[34] of Vpr during viral infection has been identified as a
key requirement for virion incorporation. With this in
mind, we assessed the ability of nuclear import-inhibited
cytosolic GFP-VprF72L to incorporate into forming virions.
Briefly, 293T cells were cotransfected with a panel of GFP-
Vpr expression vectors as well as the proviral plasmid
pUC18-NL4.3, with the resultant virions analysed by
Western blotting for GFP-Vpr incorporation. Interestingly
we found that all F72L-containing GFP-Vpr proteins that
failed to significantly localize within the nucleus, were
absent from purified viral lysates (Fig. 2A), implying a
possible link between the efficient nuclear transport of
Vpr and virion incorporation. To examine the effect of the
F72L mutation on HIV infectivity, we infected γ-irradi-
ated, non-dividing CD4+ MAGI (Multinuclear Activation
of a Galactosidase Indicator) cells which contain an inte-
grated HIV-1-LTR-β-galactosidase gene with virus derived
from 293T cells cotransfected with ΔVpr pro-virus and
wildtype or F72L-containing GFP-Vpr encoding plasmids.
48 hours post infection, MAGI cells were fixed and stained
with 5-bromo-4-chloro-3-indolyl-beta-Dgalactopyrano-
side (X-gal) [35], followed by scoring for infected cells
(blue nuclei) due to LTR-β-gal transactivation by viral Tat
protein. Virus derived from all F72L-containing plasmids
showed a significant (p < 0.0001), 5-fold reduction in
viral infectivity when compared to wildtype Vpr1–96 (Fig.
2B). This dramatic reduction in infectivity presumably
stems from the lack of virion incorporation of F72L-con-Retrovirology 2008, 5:67 http://www.retrovirology.com/content/5/1/67
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Late-stage LTNP-derived GFP-Vpr samples show decreased levels of nuclear accumulation compared to wildtype Vpr and pro- gressing donors B and C Figure 1
Late-stage LTNP-derived GFP-Vpr samples show decreased levels of nuclear accumulation compared to 
wildtype Vpr and progressing donors B and C. (A) HeLa cells were transfected with indicated GFP-Vpr constructs using 
Lipofectamine 2000™ with confocal images obtained 14 hours later using an Olympus FV1000 CLSM. (B) Analysis of CLSM 
images (as per A) with ImageJ was performed to determine the Fn/c. As a whole, late-stage samples from patient A (A6-2, A6-
3, A6-4) and the Vpr (F72L) point mutant displayed significantly (p < 0.0001) reduced Fn/c ratios compared to wildtype Vpr. 
(C) Sequence analysis of patient-derived vpr sequences identifies F72L substitution mutation (as indicated) uniquely within all 
GFP-Vpr constructs with reduced nuclear accumulation.
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F72L-containing GFP-Vpr proteins fail to incorporate into forming virions, which show decreased infectivity of non-dividing  MAGI (Multinuclear Activation of a Galactosidase Indicator) cells correlating with reduced importin-β3 binding Figure 2
F72L-containing GFP-Vpr proteins fail to incorporate into forming virions, which show decreased infectivity of 
non-dividing MAGI (Multinuclear Activation of a Galactosidase Indicator) cells correlating with reduced 
importin-β3 binding. (A) Virus was derived from 293T cells cotransfected with pEPI-GFP-Vpr and proviral plasmid pUC18-
NL4.3 and subjected to Western blot analysis, revealing the absence of GFP-Vpr protein in F72L containing samples. Control 
staining for p24 capsid protein indicates the presence of virus in all samples (*denotes lack of virion incorporation). (B) Virus 
derived from 293T cells cotransfected with the ΔVpr pro-viral plasmid pUC18-NL4.3(FS) and pEPI-GFP-Vpr (1–96, A6-2, A6-3 
or F72L) was purified, normalized using an RT assay and used to infect growth arrested (γ-irradiated, 2 cycles at 30 Gy) MAGI 
(CD4+, integrated HIV-1-LTR-β-gal) cells. 48 hours post infection cells were fixed (1% formaldehyde/0.2% glutaraldehyde/PBS), 
stained (4 mM potassium ferricyanide, 4 mM potassium ferrocyanide, 2 mM MgCl2, 0.4 mg/ml 5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside [X-gal]) and scored for viral infectivity. Infected cells display X-gal stained (blue) nuclei due to expression of 
the early HIV protein Tat, which binds the HIV-LTR promoter of the integrated β-gal gene, resulting in expression of the β-gal 
protein. Non-infected cells remain colourless due to the lack of Tat expression and subsequent activation of the β-gal gene. 
Data presented depicts relative levels of infectivity (% +/- SEM) compared to wildtype Vpr1–96. Virus derived from F72L-
cotransfected 293T cells displayed a significant (p < 0.0001) 5-fold reduction in viral infectivity of non-dividing cells compared 
to wildtype Vpr1–96. (C) Native PAGE gel-shift mobility assay; 2 μM GFP-Vpr1–96 or GFP alone was incubated with 10 μM 
importin-α2, -β1, -α2/β1 or -β3 as indicated. (D) Native PAGE gel-shift mobility titration assay; (i) 2 μM GFP-Vpr1–96 or GFP-
VprF72L was incubated with increasing concentrations of Importin-β3 protein as indicated. (ii) Fluorimetric analysis of gel-shift 
assays from D(i), was performed as per [39] with the binding curves generated used to calculate dissociation constants (Kd). 
(E)i Typical CLSM images of fixed COS-7 cells expressing the indicated GFP-fusion proteins alone or in the context of c-myc-
tagged-human Importin-β3. Cells were permeabilised and stained 14 hours post transfection with anti-c-myc antibody (Sigma) 
and visualized with Alexa-Fluo-568 (Molecular Probes). (E)ii Analysis of CLSM images (as per E(i)) with ImageJ was performed 
to determine the Fn/c. Exogenous Importin-β3 was found to significantly (p = 0.0378) increase the nuclear accumulation of 
wildtype GFP-Vpr1–96, but not that of GFP-VprF72L or F72L containing GFP-VprA6-3.Retrovirology 2008, 5:67 http://www.retrovirology.com/content/5/1/67
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taining Vpr (Fig. 2A) and resultant absence of Vpr-facili-
tated PIC nuclear import, a key factor in efficient HIV
replication within non-dividing cells [1,24,25,36].
Nuclear accumulation of Vpr is governed by 2 distinct
NLSs; a leucine-rich N-terminal α-helix (20LELLEEL26)
which has been linked to virion incorporation [37,38],
and a C-terminal arginine-rich bipartite (underlined)
(71HFRIGCRHSRIGVTRQRRAR90) NLS [27] which incor-
porates phenylalanine 72 (bold). To determine if the
identified F72L substitution affects the function of Vpr's
C-terminal NLS, we used a previously described fluores-
cence based gel-shift mobility assay [39] to compare the
interaction between wildtype GFP-Vpr1–96  and GFP-
VprF72L with a panel of purified importin proteins. We
established that wildtype GFP-Vpr1–96 was able to bind
with high affinity to human Importin-β3 (hβ3) but not
other members of the importin superfamily, including
Importin-β1, Importin-α2 or the Importin-α2/β1 het-
erodimer. (Fig. 2C). Titrations revealed that GFP-VprF72L
was unable to bind hβ3 as effectively as wildtype GFP-
Vpr1–96 (Kd = 0.66 μM vs. 1.60 μM) (Fig. 2D(i, ii)), indicat-
ing a direct relationship between F72L and decreased
Importin-β3 binding capacity. In vivo cotransfection of
GFP-Vpr constructs with Importin-β3 was found to
increase the Fn/c of wildtype GFP-Vpr1–96, but not that of
GFP-VprF72L or GFP-VprA6-3, consistent with the idea that
Importin-β3 contributes to nuclear import of Vpr, and
that the F72L mutation impacts on recognition by Impor-
tin-β3 directly (see Fig. 2E(i, ii)). We therefore propose
that the F72L mutation itself leads to decreased Vpr
nuclear import and consequently reduced virion incorpo-
ration due to reduced binding efficiency to Importin-β3.
It does not seem unreasonable to speculate that in vivo
selective pressures have driven the evolution of function-
ally-attenuated vpr to ensure long-term viral survival and
replication in vivo [2,5,40-42]. Our study shows that F72L-
containing Vpr does not accumulate within host cell
nuclei or incorporate into nascent virions; subsequent
infections with such a Vpr-deficient virus are less efficient,
leading to reduced virus production [41-43] and ulti-
mately a lack of deterioration in T-cell numbers, as in the
case of the LTNP. Many of our observations are concord-
ant with analysis of LTNP infection status in 2000, which
revealed normal CD4+ T-cell levels (>550 cells per μl) sug-
gesting the absence of significant HIV-mediated T-cell tar-
geting and depletion. Since our data here suggests that c.
75% of late-stage proviral strains in the LTNP would pro-
duce virions lacking Vpr due to the F72L mutation, the
levels of observed CD4+ T-cells within the LTNP may be
due to the inability of HIV lacking Vpr to import the viral
genome into the non-dividing host cell nucleus and carry
out subsequent steps of infection [1,24,25,44]. Presuma-
bly one advantage for the virus is that the preservation of
patient health status leads to enhanced probability of
transmission to new hosts, thus leading to increased virus
spread. Low levels of virus production (<425 HIV copies/
ml plasma) [29] are presumably maintained through the
activity of a small subset of Vpr quasi-species that do not
contain the F72L mutation (A6-4) or perhaps viruses that
we were unable to characterize due to their low preva-
lence. Additional to all of the above considerations, it is
important to remember that the effects of decreased Vpr
nuclear import through the F72L mutation are likely to be
influenced by many other factors, including host genetic
make-up and immune response, which in themselves can
influence disease progression [28,45-49].
In summary this study provides evidence for a naturally
occurring Vpr mutation within an epidemiologically-
linked cohort and its possible contribution to non-pro-
gressive HIV disease status through disruption of efficient
nuclear transport and apparent lack of viral incorporation,
leading to reduced infectivity of non-dividing cells (Fig.
2B). To demonstrate formally the link between Vpr
nuclear localisation and disease progression, further anal-
ysis of VprF72L in a HIV infectious system is required, eg. to
dismiss the possibility that the effects in terms of lack of
assembly of VprF72L may in part be due to impaired p6gag
binding, stemming from conformational or other effects.
With this proviso in mind, however, the work here and
elsewhere (see also [50]) implies that functional selection
of  vpr  viral quasispecies in concert with host selection
pressure over time, as evident in the LTNP, may be a factor
in determining the rate of disease progression.
Additional material
Additional file 1
LTNP derived Vpr proteins with reduced nuclear accumulation local-
ize within the Golgi. Typical CLSM images of fixed COS-7 cells express-
ing the indicated GFP-fusion proteins. Cells were permeabilised and 
stained 14 hours post transfection for γ-adaptin and visualized with 
Alexa-Fluor-568. GFP-Vpr proteins specifically containing F72L show 
colocalisation with the Golgi apparatus as indicated by arrows.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1742-
4690-5-67-S1.ppt]
Additional file 2
LTNP derived Vpr proteins with reduced nuclear accumulation local-
ize within the Golgi. Typical CLSM images of fixed COS-7 cells express-
ing the indicated GFP-fusion proteins. Cells were permeabilised and 
stained 14 hours post transfection for Calnexin and visualized with Alexa-
Fluor-568. GFP-Vpr was found to not localize within the ER.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1742-
4690-5-67-S2.ppt]Retrovirology 2008, 5:67 http://www.retrovirology.com/content/5/1/67
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